

## CORPORATE SYNOPSIS

T-Ray Science, Inc. is a medical device company centered on the development and commercialization of an innovative skin cancer detection system for the early diagnosis and treatment of all significant forms of skin cancer, including: melanoma, basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).

The Company's patented imaging and spectroscopy technologies are the foundation for the development of the company's non-invasive, in vivo skin cancer detection and delineation system. This diagnostic tool will deliver significant clinical impact through improved patient outcomes, and will reduce healthcare costs by eliminating the need for most biopsies. T-Ray's platform technology is also extensible to other forms of cancer, including gastro-intestinal and cervical cancers.

T-Ray continues to build a portfolio of OEM and out-licensing agreements to support numerous research and commercial applications.

## INVESTMENT HIGHLIGHTS

- Innovative multimodality device for the safe and early detection of skin cancer
- Proprietary platform technologies  
– Strong patent portfolio
- Multiple applications in high growth markets
- Near term revenue – Growing customer base
- Established industry & academic partnerships
- Strong market comparables
- Experienced management and R&D teams

## THE MARKET PROBLEM

Skin Cancer is the most common and rapidly increasing form of cancer. Primary diagnosis is currently done via visual inspection, which results in diagnostic sensitivity that is often questionable. In most cases, treatment precedes a definitive diagnosis.

Excisional biopsy with tissue pathology is currently the most reliable diagnostic approach, but it has many drawbacks:

- Invasive and impractical for high risk patients with many lesions
- The suspicious lesion is removed in advance of the pathology
- Most biopsies are negative
- Cost of the biopsy and the pathology is significant
- Patient scarring and disfigurement


## REVOLUTIONARY PRODUCTS

### Skin Cancer Detector

T-Ray Science is building a point-of-care device for the detection and diagnosis of skin cancer. This device will pioneer a new approach for supporting the treatment of skin cancer.

The competitive advantage is derived from a novel, multimodality imaging and spectroscopy system providing in vivo pathology.

The platform is extensible and provides a long-term growth path into detecting other forms of cancer, including gi, cervical and colon cancers.



### THz Components & Technology Out-Licensing

Dual-mode THz sources and detectors, control software that may be used for a variety of medical and non-medical applications.

### Tablet Analyzer

Hand held device for testing pills and tablets in pharmacies. According to the Center for Medicines in the Public Interest, global counterfeit drug sales will reach US \$75 billion by 2010.



## RESEARCH COLLABORATIONS

Access to most advanced research labs and scientists in the cancer imaging and spectroscopy fields.



## STRATEGIC FOCUS

1. Advance development of skin cancer detector
2. Pursue technology licensing opportunities
3. Expand contract manufacturing partnerships
4. Broaden IP and technology portfolios
5. Prioritize market opportunities for endoscopic detector

## INTELLECTUAL PROPERTY PORTFOLIO

- Dual Mode TeraHertz Spectrometer
- Photonic Chip Holder
- TeraHertz Photonic Chips
- Whispering Gallery Mode Resonator
- Systems and Methods for Blind Echo Cancellation
- BCCA: Skin Cancer Detection  
- *Exclusive License Agreement*
- BCCA: In Vivo Endoscopic Probe  
- *Exclusive License Agreement*
- BCCA: Multimodal detection of tissue abnormalities  
- *Exclusive License Agreement*
- BCCA: High Speed Raman Spectroscopy  
- *Exclusive License Agreement*
- BCCA: Lung Cancer Detection  
- *Exclusive License Agreement*
- MIT: THz Imaging System  
- *Exclusive License Agreement*
- RWTH Aachen: THz Chips  
- *Exclusive License Agreement*

## SCIENTIFIC BOARD

Safieddin Safavi-Naeini, Ph.D.  
University of Waterloo

Branko Palcic, Ph.D.  
University of British Columbia  
BC Cancer Agency

## MANAGEMENT

Thomas Braun, JD, LLM  
President and CEO

Anna Trinh, B.Comm, LLB  
Chief Financial Officer  
Corporate Counsel

## CONTACT INFORMATION

Thomas Braun, JD, LLM  
President and CEO  
E-mail: [tbraun@t-rayscience.com](mailto:tbraun@t-rayscience.com)



306 - 2309 West 41st Avenue  
Vancouver, BC V6M 2A3  
Tel. (604) 605-0507  
Fax (604) 605-0508  
<http://www.t-rayscience.com>  
TSX-V: THZ